AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

ABCL575 is an Fc-silenced, half-life extended investigational antibody therapy that is being developed for the treatment of atopic dermatitis

AbCellera (Nasdaq: ABCL) today announced it has dosed the first participants in its Phase 1 clinical trial of ABCL575, a next-generation investigational antibody therapy being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications for other inflammatory and autoimmune conditions. ABCL575 targets OX40 ligand and has been engineered to support a dosing interval of once every six months, which is less frequent than current clinical-stage molecules.

The Phase 1 clinical trial of ABCL575 ( NCT07108894 ) is a randomized, placebo-controlled, double-blind study to assess safety and tolerability in healthy participants following subcutaneous doses of ABCL575. Data from this study is expected in mid 2026.

About ABCL575

ABCL575 is an Fc-silenced, half-life extended investigational antibody therapy being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications for other inflammatory and autoimmune conditions. ABCL575 binds OX40 ligand (OX40L) to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In preclinical studies, ABCL575 shows potent inhibition of T cell-mediated inflammatory pathways, favorable safety profile, and an in vivo half-life that is expected to support less frequent dosing than current clinical-stage molecules.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit www.abcellera.com .

AbCellera Forward-Looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250827224300/en/

Inquiries
Media: Tiffany Chiu; media@abcellera.com , +1(236)521-6774
Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com , +1(604)559-9005
Investor Relations: Peter Ahn; ir@abcellera.com , +1(778)729-9116